688266.SH
泽璟制药-U
SSE · Healthcare · Biotechnology · CN
CNY 117.83
−8.45%Margins
Gross margin
94.5%
EBITDA margin
-7.8%
EBIT margin
31.9%
Net margin
32.2%
FCF margin
40.9%
29.1%
Return on equity
13.5%
Return on assets
18.7%
Return on invested capital
0.47x
Asset turnover
CNY 814.9M
Cash from operations
—
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Mar 1, 2026